Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine in septic shock
IRCT20260718070234N1Phase 3Recruiting
- Sponsor
- Kerman University of Medical Sciences
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexmedetomidine in septic shock (2 arms), sponsored by Kerman University of Medical Sciences. Primary endpoints: Mean arterial pressure and Norepinephrine dose. Started Sep 2026; status: recruiting.
02
Drugs
dexmedetomidine
03
Conditions
septic shock
Beyond the preview
Go deeper on IRCT20260718070234N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260718070234N1.